Compare General Motors Company (GM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Eli Lilly And Co — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 14.4× General Motors Company's market cap, and General Motors Company pays the higher dividend (0.88%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Eli Lilly And Co for 93 Days on average.
| GM | LLY | |
|---|---|---|
Market Cap | $72.17B | $1.04T |
Volume | 4,900,304 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $1.28K |
52-Week Low | $55.35 | $799.57 |
Typical Hold Time | 83 Days | 93 Days |
Enterprise Value | $175.15B | $1.09T |
Dividend Yield | 0.88% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.73, up 2.15% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong operating cash flow of $26.87B in 2025 but declining profit margins. Recent Q3 2026 sales fell 5.5% as EV demand weakens and Toyota challenges GM's U.S. sales leadership. Analyst consensus remains bullish with a $102.08 price target, though technical indicators show resistance at $83-$85 levels.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but cost savings from eased fuel economy rules ($20.4B through 2031) and strong cash generation provide stability. The stock trades at attractive valuations (P/S 0.42) with 67% analyst buy ratings, though competitive threats and EV transition challenges require monitoring for sustained recovery.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
